The global Vaccines Market Size was valued at US$ 42 billion in 2021 and is expected to grow at a 10% CAGR between 2022 and 2032, reaching around US$ 120 billion by 2032. The rising prevalence of chronic and infectious diseases, as well as rising vaccine demand in developed and developing countries, are driving growth in the vaccines market.

As the world experiences frequent disease outbreaks, governments and healthcare institutions are constantly looking for ways to combat these diseases while minimising the economic burden caused by these outbreaks. Vaccination is one such approach.

Vaccines have become highly sought-after healthcare products used for disease prevention and treatment. These vaccines significantly boost an individual's immune system, providing longer protection against diseases. They have made significant contributions to the control of diseases such as polio and smallpox. The growing preference for vaccines to improve immunity against diseases is a major factor driving the growth of the vaccines market.

Vaccines Market: Segmentation

Valuable information covered in the FMI’s Vaccines market report has been segregated into key segments and sub-segments.

By Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Viral Vector Vaccines

By Type:

  • Monovalent Vaccines
  • Multivalent Vaccines

By Route of Administration:

  • Intramuscular & Subcutaneous Administration
  • Oral Administration
  • Other routes (Intranasal, Intradermal and Percutaneous)

By Disease Indication:

  • Influenza
  • Pneumococcal Diseases
  • Combination Vaccines
  • HPV
  • Herpes Zoster
  • Meningococcal Diseases
  • Rotavirus
  • MMR
  • Varicella
  • Hepatitis
  • DTP
  • Polio
  • Covid-19
  • Other Disease Indications (Cancer, Dengue, Tuberculosis, Typhoid, Japanese Encephalitis, Rabies, Yellow Fever, and Allergies)

By End User:

  • Pediatric Vaccines
  • Adult Vaccines

Browse More@

Key players covered in the report include:

Sanofi SA, Merck & Co., Inc, Pfizer BioNTech, CSL Limited, Johnson & Johnson (J&J), Emergent Biosolutions Inc., AstraZeneca plc, Bavarian Nordic A/S, and Mitsubishi Tanabe Pharma Corporation